𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetic and Pharmacodynamic Changes During the First Four Years of Levodopa Treatment in Parkinson’s Disease

✍ Scribed by Phylinda L. S. Chan; John G. Nutt; Nicholas H. G. Holford

Publisher
Springer
Year
2005
Tongue
English
Weight
219 KB
Volume
32
Category
Article
ISSN
1573-8744

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Genetic polymorphism of catechol-O-methy
Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic–pharmacodynamic pattern in patients with Parkinson's disease
✍ Manuela Contin; Paolo Martinelli; Mirella Mochi; Roberto Riva; Fiorenzo Albani; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

## Abstract We explored the potential effect of catechol‐__O__‐methyltransferase (COMT) genetic polymorphism on the pharmacokinetics and pharmacodynamics of a standard oral dose of levodopa in patients with Parkinson's disease (PD). We prospectively collected blood samples for COMT genotyping from

Motor response to levodopa and the evolu
Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease
✍ Craig D. McColl; Katrina A. Reardon; Mark Shiff; Peter A. Kempster 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 935 KB

Thirty-four patients with Parkinson's disease were followed for a mean period of 8 years from the time of initiation of levodopa medication. Levodopa response was charted from the starting point of pharmacological treatment to give a longitudinal point of view of the changes that evolve as the disea

Safety of entacapone and apomorphine coa
Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study
✍ Jan C.M. Zijlmans; Berengere Debilly; Olivier Rascol; Andrew J. Lees; Franck Dur 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

## Abstract We investigated whether administration of the catechol‐__O__‐methyl transferase (COMT) inhibitor entacapone, at doses of 200 mg and 400 mg, alters the pharmacokinetics of apomorphine in Parkinson's disease patients experiencing severe motor fluctuations. In addition, the pharmacodynamic

Ropinirole in the treatment of early Par
Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study
✍ Dr. Olivier Rascol; David J. Brooks; Ehrout R. Brunt; Amos D. Korczyn; Warner H. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 785 KB

The efficacies of ropinirole and levodopa were compared after 6 months of treatment in a planned interim analysis of a 5-year, double-blind, randomized, multicenter study of patients with early Parkinson's disease requiring dopaminergic therapy. The percentage of improvement in the Unified Parkinson